Showing results (131-140 of 259) with videos related to

Sort By:
Pageof 26
British Journal of Haematology|July 30, 2021
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphomaRui Lyu, Tingyu Wang, Yi Wang, et al.
Oncotarget|March 21, 2016
Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosisMu Hao, Meirong Zang, Lei Zhao, et al.
Blood Science (Baltimore, Md.)|June 4, 2024
Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)Gang An, Zheng Ge, Hongmei Jing, et al.
Annals of Hematology|December 4, 2023
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)Lihui Shi, Wenqiang Yan, Jingyu Xu, et al.
Hematology (Amsterdam, Netherlands)|September 19, 2023
The age-dependent changes in risk weights of the prognostic factors for multiple myelomaChenxing Du, Lingna Li, Huishou Fan, et al.
Cancer Research Communications|September 8, 2023
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction TreatmentJiahui Liu, Wenqiang Yan, Huishou Fan, et al.
The Journal of Biological Chemistry|September 6, 2013
Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysisHuiling Cao, Ke Zhu, Lugui Qiu, et al.
American Journal of Hematology|August 6, 2014
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myelomaChuanying Geng, Jian Hou, Yaozhong Zhao, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myelomaJian Cui, Tengteng Yu, Rui Lv, et al.
Advances in Therapy|November 19, 2020
Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myelomaJianming He, Luke Schmerold, Rian Van Rampelbergh, et al.
Pageof 26